P&G's vitamin boost could signal more to come
Reuters
Published Apr 20, 2018 01:07AM ET
P&G's vitamin boost could signal more to come
By Martinne Geller and Richa Naidu
LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products.
The U.S.-based maker of Tide detergent and Gillette razors announced the deal on Thursday, giving it brands such as Seven Seas vitamins and expanding its portfolio of healthcare products.
Just last month, cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for $700 million. And in December, Nestle SA (SIX:NESN) paid $2 billion for vitamin maker Atrium Innovations.
The moves show how global consumer goods companies are looking to new, interesting areas to offset flagging growth in their core businesses.
The vitamins and supplements sector is attractive due to the emergence of new brands marketing themselves digitally and selling directly online to young consumers, said investment banker William Hood of William Hood & Co.
"It's what the millennials are buying and how they're buying it," Hood said. "Large companies are realizing they need to figure it out."
A spokeswoman for P&G declined to comment on the company's strategy to expand its vitamins, minerals and supplements business. P&G already owns consumer health brands including Vick's, Metamucil and Pepto-Bismol.
Globally, the vitamin and supplements category has grown between 5 and 7 percent annually for the past five years, according to Euromonitor.
The category is very fragmented, with market leader Amway Corp having only 3.6 percent share, Euromonitor data showed. That implies a consolidator could easily boost margins by building scale.
Consumer goods firm Reckitt Benckiser has owned Schiff, maker of MegaRed tablets for heart health and Airborne for immunity, for five years. It was a very different business to other health or home goods, said CEO Rakesh Kapoor on a post-earnings call in February, adding that sales and margins were improving after some stumbles.
"This is a category which is here to stay. It is one of the single largest categories in health," he said.
A PRELUDE TO MORE?
P&G was in talks with Pfizer (NYSE:PFE) about buying the U.S. drugmaker's consumer health business, CNBC reported earlier this month. Pfizer hoped to bring in $20 billion through an auction for the business, which includes Centrum vitamins and Advil painkillers.
The auction hit a roadblock after GlaxoSmithKline and Reckitt Benckiser dropped out of the running.
When asked about its interest in Pfizer on Thursday, P&G chief executive David Taylor declined to comment.
Get The News You Want
Referring to the P&G-Merck deal, Liberum analyst Robert Waldschmidt said: "The question is - is it a prelude to more? ... Is P&G still theoretically on the hunt for Pfizer?"
Bernstein analysts noted that the Pfizer business "may still be an acquisition candidate (for P&G) since it doesn't seem to raise anti-trust concerns on the surface."
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.